the efficacy of icis for melanoma in-transit nodal metastases with or without nodal metastasis
Published 2 years ago • 127 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
0:39
pembrolizumab, emavusterib radiosurgery: a novel trimodal therapy for metastatic melanoma
-
4:27
key updates in immunotherapies for melanoma
-
0:46
the benefits of nivolumab and relatlimab in melanoma
-
1:27
validating mia & mskcc predictive tool for melanoma sentinel node status
-
3:30
side effects of immune checkpoint inhibitors
-
1:48
influence of new immunotherapy checkpoint inhibitors in melanoma
-
0:36
challenges associated with implementing ctdna approaches in melanoma
-
0:50
key findings from the fact-m questionnaire in patients with melanoma
-
33:10
immune checkpoint inhibition in myeloid malignancies
-
1:00
the clinical potential of cellular therapeutics in melanoma
-
2:27
key cellular therapy updates in melanoma
-
2:25
liquid biopsies to predict response to i-o in metastatic melanoma
-
0:58
what are immune checkpoints?
-
2:45
correlation between cutaneous immune-related adverse events and os with immune checkpoint inhibitors
-
4:00
earlier use of checkpoint inhibitors
-
1:27
analyzing the role of checkpoint inhibitors for the treatment of melanoma
-
29:04
melanoma update
-
7:11
checkpoint inhibitors in metastatic melanoma
-
0:57
skin cancer highlights at asco 2022